Overview

Efficacy and Safety of Gemigliptin 50mg qd Added in Patients With Type 2 Diabetes Inadequately Controlled on Glimepiride and Metformin

Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
After a screening, a 2-week, single-blind placebo run-in, 174 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Gemigliptin 50 mg or placebo to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.
Phase:
Phase 3
Details
Lead Sponsor:
LG Life Sciences